WINTON GROUP Ltd boosted its stake in shares of STAAR Surgical Company (NASDAQ:STAA – Free Report) by 14.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 147,822 shares of the medical instruments supplier’s stock after buying an additional 18,716 shares during the quarter. WINTON GROUP Ltd’s holdings in STAAR Surgical were worth $3,413,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its position in STAAR Surgical by 2,605.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 1,016 shares during the period. Russell Investments Group Ltd. grew its position in shares of STAAR Surgical by 9,928.9% in the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock valued at $121,000 after purchasing an additional 4,468 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of STAAR Surgical by 375.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 4,673 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of STAAR Surgical in the third quarter valued at approximately $208,000. Finally, Amundi acquired a new stake in shares of STAAR Surgical in the third quarter valued at approximately $251,000. 96.70% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at STAAR Surgical
In other news, Director Broadwood Partners, L.P. bought 316,017 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average price of $18.61 per share, for a total transaction of $5,881,076.37. Following the completion of the transaction, the director owned 16,123,842 shares in the company, valued at $300,064,699.62. The trade was a 2.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased a total of 670,213 shares of company stock worth $12,266,249 in the last quarter. 39.90% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on STAAR Surgical
STAAR Surgical Price Performance
Shares of NASDAQ STAA opened at $29.99 on Monday. STAAR Surgical Company has a 1 year low of $15.59 and a 1 year high of $35.87. The firm’s 50 day moving average price is $26.58 and its 200 day moving average price is $23.11. The firm has a market cap of $1.49 billion, a P/E ratio of -69.74 and a beta of 1.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.31 and a current ratio of 5.12.
STAAR Surgical (NASDAQ:STAA – Get Free Report) last announced its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The firm had revenue of $93.52 million for the quarter, compared to analyst estimates of $78.72 million. During the same quarter last year, the business earned ($1.10) earnings per share. STAAR Surgical’s revenue was up 119.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that STAAR Surgical Company will post 0.13 earnings per share for the current year.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
Read More
- Five stocks we like better than STAAR Surgical
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical Company (NASDAQ:STAA – Free Report).
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
